Grifols snags the rest of GigaGen in $80M acquisition; Vertex moves cutting-edge diabetes treatment into the clinic
Spain’s Grifols is putting up $80 million to buy out the 56% of equity in GigaGen it doesn’t already own.
Grifols execs touted its acquisition of a pipeline that includes “the world’s first recombinant immunoglobulin and a portfolio of immuno-oncological therapies.”
The Spanish biotech anted up $35 million back in the summer of 2017 to buy into GigaGen, taking its first 44% minority stake. And execs say they won’t have to take on new debt in the deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.